Holen Sie sich die Stockscreener-App
30.01
1.15%
-0.35
Schlusskurs vom Vortag:
$30.36
Offen:
$33
24-Stunden-Volumen:
93,908
Relative Volume:
0.26
Marktkapitalisierung:
$2.28B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+2.88%
1M Leistung:
-50.64%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$29.77
$34.00
1-Wochen-Bereich:
$28.32
$38.88
52-Wochen-Spanne:
$9.95
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Firmenname
Jyong Biotech Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie MENS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
30.01 | 2.31B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jyong Biotech Ltd Aktie (MENS) Neueste Nachrichten
Jyong Biotech (NASDAQ:MENS) Shares Gap UpStill a Buy? - MarketBeat
Jyong Biotech: Speculative BPH And Prostate Cancer Prevention Story (NASDAQ:MENS) - Seeking Alpha
Jyong Biotech (NASDAQ:MENS) Stock Price Down 9.6%What's Next? - MarketBeat
Taiwan's Jyong Biotech announces partnership in Korea to evaluate in‑licensing of plant-derived MCS drugs - BioSpectrum Asia
Jyong Biotech signs letter of intent with South Korean pharma company - Investing.com Nigeria
Jyong Biotech to Evaluate Licensing Deal for MCS-2 Drug Candidate in South Korea - MarketScreener
Jyong Biotech signs letter of intent with South Korean pharma company By Investing.com - Investing.com South Africa
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs - The Manila Times
Jyong Biotech (Nasdaq: MENS) LOI to Evaluate MCS-2 Licensing with Korean Pharma - Stock Titan
Jyong Biotech (NASDAQ:MENS) Shares Up 10.9%Should You Buy? - MarketBeat
Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8 - Yahoo Finance
Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price Volatility - Yahoo Finance
Jyong Biotech reports positive results for prostate cancer drug in phase II trial - Investing.com Nigeria
Jyong Biotech stock soars after positive Phase II prostate cancer drug results - Investing.com Nigeria
Jyong Biotech stock soars after positive Phase II prostate cancer drug results By Investing.com - Investing.com South Africa
Jyong Biotech Says Phase 2 Trial of MCS-8 in Prostate Cancer Meets Efficacy Endpoints - MarketScreener
Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes - The Manila Times
Jyong Biotech (Nasdaq: MENS) MCS-8 Phase II Cuts Prostate Cancer 27%, High-Grade 17% - Stock Titan
Jyong Biotech (NASDAQ:MENS) Shares Gap DownTime to Sell? - MarketBeat
Jyong Biotech Ltd. (MENS) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Jyong Biotech is Now Oversold (MENS) - Nasdaq
Jyong Biotech plunges 49% after InvestingPro’s overvalued warning By Investing.com - Investing.com Australia
Google, Alibaba among market cap stock movers on Monday - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Google and Micron among market cap stock movers on Monday By Investing.com - Investing.com UK
Google and Micron among market cap stock movers on Monday - Investing.com India
Jyong Biotech (MENS US): Taiwan-Based, US-Listed, Excluded from US & Global Indices - Smartkarma
Jyong Biotech (NASDAQ:MENS) Trading Down 8%Here's Why - MarketBeat
Dow notches record-high close while tech-heavy Nasdaq slips - Yahoo Finance
Dow notches record high close, traders bet on end to shutdown - Yahoo Finance
Health insurers slide after subsidies dropped from US shutdown deal - Yahoo Finance
Global shares jump as investors eye potential end to US shutdown - Yahoo Finance
Wall Street ends higher on solid data, strong earnings - Yahoo Finance
OpenAI signs $38 billion deal to use Amazon's cloud platform - Yahoo Finance
'Hopeful' We'll Find Long-term Solution On China: Illumina CEO - Yahoo Finance
Jyong Biotech (NASDAQ:MENS) Stock Price Up 11.2%Here's What Happened - MarketBeat
FLOWSERVE CORPORATION (FLS) Stock, Price, News, Quotes, Forecast and Insights - MSN
Caterpillar Posts Upbeat Q3 Results, Joins United Therapeutics, Centene, Fortive And Other Big Stocks Moving Higher On Wednesday - Benzinga
Caterpillar, Nvidia Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com Nigeria
Caterpillar, Nvidia Lead Market Cap Stock Movers on Wednesday - Investing.com India
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results - Yahoo Finance
Jyong Biotech (NASDAQ:MENS) Stock Price Down 15.6%Here's Why - MarketBeat
Tesla and Nvidia lead market cap stock movers this Tuesday - Investing.com
Downgrade Sparks Sharp Fall in Jyong Biotech MENS Stock, Yet Support Holds - FXLeaders
Here's How Much Traders Expect Meta Stock To Move After Earnings This Week - Yahoo Finance
Tesla and Qualcomm Lead Monday’s Market Cap Stock Movers - Investing.com
Tesla and Qualcomm Lead Monday’s Market Cap Stock Movers By Investing.com - Investing.com UK
New Montreal Biotech LifeLore Pathways Launches to Accelerate Microbial Innovation - Yahoo Finance
Jyong Biotech's (MENS) "Sell (E+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
BNB Jumps on CZ's Pardon - Yahoo Finance
Finanzdaten der Jyong Biotech Ltd-Aktie (MENS)
Es liegen keine Finanzdaten für Jyong Biotech Ltd (MENS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.76%
2.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):